Macular Degeneration Treatment in China: How We Arrange Your Care
When 67-year-old Margaret from Manchester noticed the straight lines of her window frame starting to wave, her optometrist said the words she’d been dreading: wet age-related macular degeneration. The NHS waiting list for her first injection stretched to six weeks. Her vision was already blurring in the center of her left eye. She started searching for alternatives that wouldn’t bankrupt her retirement savings. That search led her to questions about macular degeneration treatment cost China — and to us.
Here’s the direct answer: anti-VEGF injections in China’s top-tier public hospitals typically run between $400 and $1,200 per injection, depending on the drug and the hospital tier. In the United States, the same medications cost $1,800 to $2,500 per dose before insurance. That’s a 60–80% reduction. But cost is only part of the story. Getting treated in China requires navigating a system that doesn’t work like Western healthcare — and that’s where the real question of whether this path makes sense for you begins.
Macular Degeneration Treatment Cost China: The Short Answer
For most international patients, macular degeneration treatment cost China lands between $400 and $1,200 per anti-VEGF injection. The three drugs used — ranibizumab (Lucentis), aflibercept (Eylea), and the off-label bevacizumab (Avastin) — are all available in Chinese hospitals. Bevacizumab is the cheapest option, sometimes under $200 per injection in public hospitals, while branded ranibizumab and aflibercept sit at the higher end of the range.
But the per-injection price isn’t the full financial picture. You’ll also pay for initial diagnostics — OCT imaging, fluorescein angiography, and a comprehensive retina exam. Those add roughly $200 to $500. Then there’s the coordination layer: hospital registration, translation of your medical records, bilingual accompaniment during visits. None of this is covered by most international insurance plans at the point of service in Chinese public hospitals.
The real savings emerge over a treatment course. Wet AMD typically requires three initial monthly injections, then maintenance dosing every 8–12 weeks. Over a year, that’s 6–8 injections. In the US, that’s $12,000–$20,000 out of pocket if you’re uninsured or underinsured. In China, even with branded drugs and coordination fees, most patients spend $5,000–$9,000 for the same year of treatment.
Who This Is Right For — and Who It Isn’t
This path isn’t for everyone. Being honest about that protects you from wasting time and money.
Good candidates typically include:
– Patients with a confirmed diagnosis of wet AMD who’ve already had OCT imaging and fluorescein angiography
– People facing long public-health wait times at home — six weeks or more for initial injection
– Uninsured or high-deductible patients in the US, or those in countries where anti-VEGF drugs are not subsidized
– Patients who can commit to staying in China for at least the first treatment cycle (4–6 weeks)
– Those comfortable with a different clinical culture — shorter consultations, more patients in the department, less hand-holding
Who should not pursue this:
– Patients with unstable cardiovascular disease or recent stroke — anti-VEGF injections carry small but real systemic risks, and long-haul travel adds strain
– Anyone whose eye condition is undiagnosed or only suspected — you need a confirmed diagnosis before any hospital will treat you
– Patients who need ongoing care coordination with a home retina specialist but have no local ophthalmologist willing to accept shared care
– Those expecting Western-style private-clinic amenities in a public hospital setting
If you’re in the second group, staying home and working through your local system is genuinely the better call. We tell people this directly.
The Options, Compared
When Margaret asked us to lay out her choices, we showed her this table. It’s the same one we show every AMD patient who contacts us.
| Option | Cost per Injection | Wait Time to First Injection | Language Support | Best For |
|---|---|---|---|---|
| US Private Ophthalmology | $1,800–$2,500 | 1–2 weeks | Native English | Fully insured patients |
| UK NHS | Free at point of service | 4–8 weeks | Native English | Patients who can tolerate waiting |
| China Public Hospital (standard channel) | $400–$800 | Same-day, but requires in-person registration | Minimal English | Mandarin speakers or those with companions |
| China Public Hospital (international/VIP department) | $800–$1,200 | 1–3 days after records review | English-speaking staff | International patients wanting coordinated access |
| China Private International Hospital (United Family, Jiahui, Raffles) | $1,000–$1,500 | 2–5 days | Full English | Patients who want Western-style care and direct insurance billing |
The standard public channel is cheap but nearly impossible to arrange from overseas. You can’t pre-book an outpatient appointment online without a Chinese ID and local payment method. You show up, queue at 6 AM, and hope. The international department route costs more but is bookable in advance — and that’s the channel we use for our patients. Private international hospitals offer the smoothest experience but at prices closer to Western levels, which defeats the savings purpose for most people.
How Is Macular Degeneration Treated in China: The Clinical Reality
The treatment protocol in China follows the same evidence base as Western ophthalmology. Anti-VEGF therapy is the first-line treatment for wet AMD, delivered via intravitreal injection — a fine needle through the sclera into the vitreous cavity. The procedure takes under five minutes. Numbing drops are applied first. Most patients feel pressure but not pain.
Chinese retina specialists follow the treat-and-extend or pro re nata (PRN) dosing regimens that are standard globally. The initial loading phase is three monthly injections. After that, the doctor uses OCT imaging to decide whether to extend the interval between doses. This is not experimental medicine. It’s the same ranibizumab and aflibercept you’d receive in London or Los Angeles.
What differs is the clinical environment. A top-tier Chinese ophthalmology department may see 500–800 outpatients daily. Your consultation might last 10 minutes, not 30. The doctor will be highly competent but unlikely to explain every nuance unless you ask. That’s why having a bilingual companion who can translate your questions — and the doctor’s answers — changes the quality of the experience dramatically.
One thing worth knowing: is anti VEGF injection safe in China is a question we hear often. The short answer is yes, when performed in accredited hospitals using genuine, properly stored medication. China’s top ophthalmology centers — the Eye and ENT Hospital of Fudan University in Shanghai, Beijing Tongren Hospital, and Zhongshan Ophthalmic Center in Guangzhou — perform tens of thousands of intravitreal injections annually. Their infection-control protocols match international standards. The risk of endophthalmitis, the most serious complication, is below 0.1% in these centers. But counterfeit or mishandled medication is a real risk in unregulated clinics. Never pursue treatment outside a top-tier public hospital or JCI-accredited private hospital.
Best Eye Hospital for AMD in Shanghai: Where We Send Patients
If you search for the best eye hospital for AMD in Shanghai, one name dominates: the Eye and ENT Hospital of Fudan University. It’s ranked among China’s top ophthalmology departments in the Fudan specialty rankings and performs over 20,000 intravitreal injections per year. Its retina service is one of the largest in Asia.
Beijing Tongren Hospital is the northern equivalent — a massive ophthalmology center with a reputation built over a century. For patients in southern China or Southeast Asia, Zhongshan Ophthalmic Center at Sun Yat-sen University in Guangzhou is the reference center. All three are public hospitals with international departments that accept foreign patients.
We typically recommend Shanghai for AMD patients for a practical reason: the Eye and ENT Hospital’s international department is experienced with foreign patients, and the city’s infrastructure makes a multi-week stay manageable. You can read more about these institutions on our top-ranked hospital database or browse our ophthalmology department rankings.
If you prefer a private setting, Jiahui Health and United Family Shanghai both have English-speaking ophthalmologists and direct billing with major international insurers. They’re more expensive but offer a familiar clinical atmosphere.
What It Costs: A Realistic Budget
Here’s a realistic budget for a first treatment cycle in China — three injections over approximately three months, with the first month on-site and follow-up injections arranged according to your doctor’s schedule.
| Item | Typical Range (USD) | Notes |
|---|---|---|
| Initial diagnostic workup (OCT, angiography, consultation) | $200–$500 | Required before first injection |
| Anti-VEGF injection (per dose, branded drug) | $400–$1,200 | Bevacizumab cheaper; ranibizumab and aflibercept at higher end |
| Three-injection loading phase | $1,200–$3,600 | Monthly intervals |
| Bilingual medical companion | from $300/day | Half-day or full-day; see our service page |
| Hospital appointment coordination | from $300 | Refunded if we cannot secure the appointment |
| Accommodation (Shanghai, 4 weeks) | $1,500–$3,000 | Serviced apartment or mid-range hotel |
| Visa and travel | $500–$1,500 | Varies by country of origin |
Total for a first cycle: roughly $5,000–$10,000, all in. Compare that to $15,000+ for the same three injections and diagnostics in the US private system.
What drives variance: the drug your doctor prescribes, the hospital tier, whether you need a translator, and how long you stay. Prices also shift with exchange rates and hospital policy updates. Final quotes always come from the hospital after reviewing your records.
Practical Considerations: Records, Visa, Payment, and Follow-Up
The logistics matter as much as the medicine. Here’s what actually happens when you pursue AMD treatment in China.
Medical records. You need your complete ophthalmology file: OCT images, fluorescein angiography, visual acuity measurements, injection history, and the referring doctor’s summary. We translate these into Chinese before your first consultation. Without them, the hospital will repeat every test — adding cost and delay.
Visa. Medical treatment in China falls under the S2 visa category, which covers short-term private affairs including medical care. Your accompanying family member also applies for an S2. The hospital’s international department will issue an invitation letter and treatment confirmation document to support your application. Processing typically takes 1–3 weeks depending on your home country’s Chinese embassy or consulate. We guide you through this but never guarantee approval — that decision rests entirely with the visa officer.
Payment. Chinese public hospitals require prepayment. You’ll deposit funds at registration and draw down as services are provided. Credit cards are accepted at international departments, though some smaller hospitals prefer UnionPay or cash. Private international hospitals accept major international cards and often bill insurers directly. Keep every receipt for insurance reimbursement at home.
Language. This is the single biggest friction point. Even in international departments, administrative staff may have limited English. Pharmacy instructions, injection schedules, and post-procedure care sheets are often in Chinese. A bilingual companion handles all of this — queueing, payment, translation, and making sure you understand exactly what the doctor said.
Follow-up after returning home. AMD is a chronic condition. You’ll need injections every 8–12 weeks for years, not months. Most of our patients do their initial treatment cycle in China, then return home with a detailed treatment summary and continue injections with their local ophthalmologist. Your Chinese doctor can provide a written protocol that your home doctor can follow. Some patients return to China once or twice a year for reassessment. This shared-care model works — but only if your home ophthalmologist is willing to accept it. Confirm that before you book a flight.
Frequently Asked Questions
Yes, when performed in top-tier public hospitals or JCI-accredited private facilities. The complication rate for intravitreal injections in China’s leading ophthalmology centers is comparable to Western benchmarks — endophthalmitis occurs in fewer than 1 in 1,000 procedures. The danger lies in unregulated clinics and unverified medication sources. Stick to Fudan Eye and ENT Hospital, Beijing Tongren, Zhongshan Ophthalmic Center, or accredited private hospitals, and the risk profile is the same as at home.
You can book the initial consultation and diagnostic workup, but no hospital will schedule an injection without first examining you in person. The international department will review your translated records, confirm you’re a suitable candidate, and arrange a consultation slot. The injection happens during that visit if the doctor confirms the diagnosis. We coordinate this entire pre-arrival process, but the clinical decision always rests with the treating physician.
Beijing Tongren Hospital’s international department is the standard answer. It’s a public hospital, so prices remain far below Western private care, but the international department provides English-speaking coordination. A consultation with a retina specialist there costs roughly $100–$200, and injections run $500–$1,000 depending on the drug. If you want a fully private experience, United Family Beijing has retina specialists with direct insurance billing, but expect prices closer to $1,200–$1,500 per injection.
Anti-VEGF therapy stabilizes or improves vision in approximately 90% of wet AMD patients, but it doesn’t help everyone. If your OCT shows persistent fluid after the loading phase, your doctor may switch drugs or add photodynamic therapy — both available in Chinese hospitals. If treatment fails, you return home with full documentation of what was tried. We cannot guarantee outcomes, and no reputable hospital will either. What we can guarantee is that you’ll receive the same standard of care you’d get at home, with full transparency about your condition throughout.
Your Next Step
Macular degeneration doesn’t wait, and neither should you. The cost difference between China and Western private care is real — often 60–80% — and the clinical quality at top Chinese ophthalmology centers matches international standards. But the logistics are not for the faint-hearted. Language barriers, hospital registration, visa paperwork, and follow-up coordination are exactly where things go wrong for patients who try to manage alone.
That’s what China Medical Services exists to handle. We’re not a hospital and we don’t diagnose or treat anything. We’re the coordination layer between you and China’s top ophthalmology departments — translating records, securing appointments through official international channels, and putting a bilingual companion beside you at every visit. Our service starts with a free consultation to assess whether this path fits your situation. If it doesn’t, we’ll tell you so.
Start with a free consultation — no commitment, no pressure, just an honest conversation about your options.
The core message is simple: China offers world-class AMD treatment at a fraction of Western private costs, but only if you navigate the system correctly. That’s the gap we fill.
For more medical information and treatment options in China, visit chinamedservices.com (China Medical Services).
